# China NMPA Drug Inspection - Shanghai Qingpu Traditional Chinese Medicine Pieces Co., Ltd. - Peach kernel (桃仁)

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/shanghai-qingpu-traditional-chinese-medicine-pieces-co-ltd/08665b59-ca8e-4d13-b9d6-7a98185197ce/
Source feed: China

> China NMPA drug inspection for Shanghai Qingpu Traditional Chinese Medicine Pieces Co., Ltd. published July 14, 2022. Drug: Peach kernel (桃仁). The National Medical Products Administration (NMPA) of China announced on July 14, 2022, findings from extensive testing

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 32 of 2022 from the National Medical Products Administration regarding 19 batches of drugs that did not meet the requirements.
- Company Name: Shanghai Qingpu Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2022-07-14
- Drug Name: Peach kernel (桃仁)
- Inspection Finding: carbonyl value
- Action Taken: Drug regulatory authorities have required relevant enterprises and units to take risk control measures such as suspending sales and use, and recalling products, and to investigate the reasons for non-compliance and implement effective rectification. The National Medical Products Administration has instructed relevant provincial drug regulatory authorities to organize investigations into the suspected illegal activities of the aforementioned enterprises and units in accordance with the "Drug Administration Law of the People's Republic of China," and to publicly disclose the results of the investigations as required.
- Summary: The National Medical Products Administration (NMPA) of China announced on July 14, 2022, findings from extensive testing by various drug institutions, identifying 19 batches of drugs from 16 companies that failed to meet regulatory standards. This announcement, NMPA No. 32 of 2022, highlighted non-compliance from manufacturers such as Ruiyang Pharmaceutical Co., Ltd., Shanghai Diran Dancheng Pharmaceutical Co., Ltd., and Tonghua Zhongsheng Pharmaceutical Co., Ltd.

Key violations involved critical quality attributes, including incorrect content determination for drugs like Erythromycin Granules and Artemisia argyi, and the presence of an undesirable impurity (hydrogen sulfide) in Acetylcysteine Injection. Other significant issues included deficiencies in physical characteristics such as appearance and disintegration time for Longze Bear Bile Capsules, along with problems in weight and content uniformity for products like Ginseng Spleen-Strengthening Pills and Fifteen-Flavor Black Pills, which also failed microbial limits. Additionally, prohibited pesticide residues were detected in Chrysanthemum, and various identification and extractive issues, as well as a high carbonyl value, were found in traditional Chinese medicines such as Rubia cordifolia and Prunus persica.

Operating under the "Drug Administration Law of the People's Republic of China" and relevant Pharmacopoeia editions, the NMPA has mandated immediate actions. These include suspending sales, use, and recalling the affected drugs. The implicated companies are required to thoroughly investigate the root causes of these non-compliances and implement effective corrective measures. Provincial regulatory authorities have been instructed to investigate any suspected illegal activities and publicly disclose their findings.

Company: https://www.globalkeysolutions.net/companies/shanghai-qingpu-traditional-chinese-medicine-pieces-co-ltd/9aa86a0a-a63c-4669-a7f7-e901f57c6796/